Key Points
- Maze Therapeutics CEO Jason Coloma sold 34,501 shares on July 1 at an average price of $29.98, totaling about $1.03 million. After the sale, he still owned 23,337 shares, and the trade was made under a pre-arranged Rule 10b5-1 plan.
- The company’s stock opened at $31.26 and has traded between a 12-month low of $10.98 and high of $53.65. Maze Therapeutics also has a market cap of about $1.73 billion and a beta of 2.14, indicating elevated volatility.
- Maze recently reported Q1 earnings of -$0.45 per share, slightly worse than analyst expectations, on $20 million in revenue. Despite mixed sentiment, analysts currently rate the stock a Buy overall with a consensus price target of $66.
Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) CMO Harold Bernstein sold 14,609 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $29.90, for a total transaction of $436,809.10. Following the completion of the sale, the chief marketing officer directly owned 14,609 shares of the company's stock, valued at approximately $436,809.10. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Harold Bernstein also recently made the following trade(s):
- On Thursday, May 14th, Harold Bernstein sold 15,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.22, for a total transaction of $393,300.00.
Maze Therapeutics Trading Up 4.9%
Shares of Maze Therapeutics stock opened at $31.26 on Friday. Maze Therapeutics, Inc. has a fifty-two week low of $10.98 and a fifty-two week high of $53.65. The company has a debt-to-equity ratio of 0.11, a quick ratio of 17.88 and a current ratio of 17.88. The company has a market capitalization of $1.73 billion, a P/E ratio of -12.36 and a beta of 2.14. The company has a fifty day moving average of $25.92 and a 200 day moving average of $35.67.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.02). The business had revenue of $20.00 million during the quarter. On average, sell-side analysts anticipate that Maze Therapeutics, Inc. will post -2.73 earnings per share for the current fiscal year.
Analyst Ratings Changes
MAZE has been the topic of several recent analyst reports. JPMorgan Chase & Co. lifted their target price on Maze Therapeutics from $52.00 to $58.00 and gave the company an "overweight" rating in a research note on Tuesday, March 31st. HC Wainwright increased their price objective on shares of Maze Therapeutics from $60.00 to $110.00 and gave the company a "buy" rating in a report on Wednesday, March 25th. Truist Financial reduced their price objective on shares of Maze Therapeutics from $68.00 to $64.00 and set a "buy" rating on the stock in a research report on Tuesday, April 14th. Wall Street Zen raised shares of Maze Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, May 16th. Finally, BTIG Research restated a "buy" rating and set a $46.00 target price on shares of Maze Therapeutics in a research report on Wednesday, March 25th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Maze Therapeutics has a consensus rating of "Buy" and a consensus price target of $66.00.
Get Our Latest Report on Maze Therapeutics
Institutional Investors Weigh In On Maze Therapeutics
Large investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Maze Therapeutics in the 1st quarter valued at approximately $57,000. Goldman Sachs Group Inc. bought a new position in shares of Maze Therapeutics during the 1st quarter valued at approximately $145,000. Rhumbline Advisers purchased a new stake in Maze Therapeutics during the 1st quarter valued at $80,000. Geode Capital Management LLC raised its holdings in Maze Therapeutics by 8.8% during the 2nd quarter. Geode Capital Management LLC now owns 231,237 shares of the company's stock valued at $2,838,000 after buying an additional 18,773 shares during the period. Finally, Legal & General Group Plc lifted its position in Maze Therapeutics by 387.0% in the second quarter. Legal & General Group Plc now owns 4,242 shares of the company's stock worth $52,000 after buying an additional 3,371 shares during the last quarter.
Maze Therapeutics Company Profile
(
Get Free Report)
Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.
Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
